Quantum-Si incorporated Stock

Equities

QSI

US74765K1051

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-24 pm EDT 5-day change 1st Jan Change
1.67 USD -1.76% Intraday chart for Quantum-Si incorporated +9.15% -16.92%
Sales 2024 * 4.08M Sales 2025 * 12.71M Capitalization 237M
Net income 2024 * -107M Net income 2025 * -111M EV / Sales 2024 * 58.1 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 18.6 x
P/E ratio 2024 *
-2.05 x
P/E ratio 2025 *
-2.04 x
Employees 159
Yield 2024 *
-
Yield 2025 *
-
Free-Float 69.52%
More Fundamentals * Assessed data
Dynamic Chart
Quantum-Si Incorporated Appoints Paula Dowdy to the Board of Directors CI
Transcript : Quantum-Si incorporated, Q4 2023 Earnings Call, Feb 29, 2024
Quantum-Si incorporated Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Quantum-Si Incorporated Provides Earnings Guidance for the Full Year 2024 CI
Earnings Flash (QSI) QUANTUM-SI INCORPORATED Reports Q4 Revenue $400,000, vs. Street Est of $0.3M MT
Quantum-Si incorporated Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Quantum-Si incorporated Expands Proteome Coverage and Increases Sequencing Output with New Enhancements to Its Next-Generation Protein Sequencing? Platform CI
Quantum-Si Introduces Next-Generation Protein Sequencertm in Japan with Addition of New Distributor CI
Quantum-Si Incorporated Introduces First Next-Generation Protein Sequencer in Japan with Addition of New Distributor, TOMY Digital Biology Co., Ltd CI
Quantum-Si incorporated(NasdaqGM:QSI) dropped from NASDAQ Biotechnology Index CI
Quantum-Si Incorporated Expands Global Reach with Addition of New Distributor, 3Genes Distribution a.s CI
HC Wainwright Initiates Quantum-Si With Buy Rating, Price Target is $3 MT
Quantum-Si Incorporated Enters into Agreement with Elta 90 to Distribute Quantum-Si?s Groundbreaking Platinum Instrument and Consumables in Southeast Europe CI
Earnings Flash (QSI) QUANTUM-SI INCORPORATED Reports Q3 Revenue $223,000, vs. Street Est of $400,000 MT
Quantum-Si incorporated Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
More news
1 day-1.76%
1 week+9.15%
Current month-15.23%
1 month-6.70%
3 months-2.34%
6 months+24.63%
Current year-16.92%
More quotes
1 week
1.48
Extreme 1.475
1.77
1 month
1.48
Extreme 1.475
2.00
Current year
1.38
Extreme 1.38
2.43
1 year
1.12
Extreme 1.12
3.90
3 years
1.12
Extreme 1.12
14.17
5 years
1.12
Extreme 1.12
25.00
10 years
1.12
Extreme 1.12
25.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 46 22-10-09
Founder 60 13-06-23
Director of Finance/CFO 51 23-05-14
Members of the board TitleAgeSince
Founder 60 13-06-23
Director/Board Member 71 21-06-09
Chief Executive Officer 46 22-10-09
More insiders
Date Price Change Volume
24-04-24 1.67 -1.76% 440,391
24-04-23 1.7 +4.94% 631,585
24-04-22 1.62 +3.18% 382,773
24-04-19 1.57 +3.97% 731,072
24-04-18 1.51 -1.31% 768,738

Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT

More quotes
Quantum-SI Incorporated is a life sciences company. The Company has designed and developed a hardware, consumable and software solution to provide a solution for protein detection and analysis. It has developed a proprietary universal single-molecule detection platform enables Next-Generation Protein Sequencing (NGPS), the ability to sequence proteins. Its launched product consists of Platinum, the Platinum Analysis Software and consumables. Its flagship protein sequencing instrument, Platinum, is designed to make the power of single-molecule detection and NGPS accessible. Platinum is designed to provide a streamlined workflow compared to legacy MS workflows. Platinum uses its proprietary semiconductor chip that leverages time-domain sequencing with an initial focus on NGPS for an unbiased view of the proteome.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
1.67 USD
Average target price
2.72 USD
Spread / Average Target
+62.87%
Consensus